Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (F.A.M.E.)
|ClinicalTrials.gov Identifier: NCT00267774|
Recruitment Status : Completed
First Posted : December 21, 2005
Results First Posted : July 27, 2016
Last Update Posted : November 13, 2017
|Condition or disease||Intervention/treatment||Phase|
|Coronary Arteriosclerosis||Device: Fractional flow reserve Procedure: Angio-guided PCI||Not Applicable|
Hide Detailed Description
- If a patient is eligible for the study (see inclusion and exclusion criteria) and has given informed consent, the operator has to define all lesions with a stenosis severity of at least 50% by visual estimate in which he would consider stent implantation. These stenoses are noted on a scheme of the coronary arteries before randomization.
- Thereafter, randomization is performed to the FFR-guided strategy or the angiography-guided strategy. If the patient is randomized to the angiography-guided strategy, all the lesions indicated beforehand, will be stented with drug-eluting stents. If the patient is assigned to the FFR-guided group, fractional flow reserve is measured in all lesions and only those lesions are stented with a fractional flow reserve </=0.80. Treatment after PCI is according to local routine and should include at least aspirin 80 mg daily and clopidogrel (Plavix) 75 mg per day for at least 12months.
- FFR should be determined by using i.v. adenosine 140 µg/kg/min, in order to make pull-back recordings and analyze different abnormalities along the coronary arteries. Adenosine i.v. by the femoral venous route, is mandatory for participation in the study.
- In case of serial stenosis, FFR 'of the complete vessel' should be </= 0.80 to warrant PCI of one of more of these lesions in case the patient belongs to the FFR-guided group. In case of the angio-guided group, every lesion >50% by visual estimation that the operator indicated a prior as requiring stenting, should be stented (this is mandatory). Long stents to cover a segment or multiple shorter stents, can be placed at the discretion of the operator.
All patients will be followed up after 1 month (±1 week), 6 months (±1 month), and 1 year (±1 month). All adverse cardiac events (death, acute MI, CABG or [re]-PCI will be noted, as well as functional class and number of anti-anginal drugs. If a patient is admitted to a hospital because of an acute coronary syndrome, repeat angiography is strongly advocated to define if the event is related to one of the deferred lesions or to one of the non-deferred lesions. If the patient belongs to the FFR-guided arm, repeat measurement of FFR is advocated for all lesions. If, during follow-up, patients in the FFR-guided group have to undergo coronary angiography because of recurrent angina or any other reason without an event, pressure measurement should be repeated as well.
On the contrary, once a patient has been assigned to the angiographic guided group, this strategy should be followed consistently during follow-up investigations. For example, if a patient in the angiographic guided arm has recurrent chest pain, undergoes angiography, and is found to have in-stent restenosis, re-PCI should be performed based on the angiogram and pressure wire use is prohibited.
In other words, the strategy to which the patient has been assigned initially, should be followed during the entire study period.
1. The primary clinical endpoint is the 12-month binary major adverse cardiac event (MACE) rate. MACE is defined as:
- All cause death,
- Documented myocardial infarction,
- Repeat revascularization (PCI and/or CABG) as adjudicated by the Clinical Event Committee
- Global cost effectiveness after one year
- Cardiac death and myocardial infarction rate at 1 year
- Functional class at 1 year.
- Number of anti-anginal drugs after 1 year
- Overall MACE rate at 1 month post-procedure and at 6 months, 2, 3 and 5 years.
- A comparison of outcomes based on type of drug-eluting stent.
- Prognostic value of FFR after stenting.
- Correlation between FFR and nuclear perfusion imaging.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||1005 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||January 2006|
|Actual Primary Completion Date :||September 2008|
|Actual Study Completion Date :||September 2015|
|Experimental: FFR guided PCI||Device: Fractional flow reserve|
|Active Comparator: Angio-guided PCI||Procedure: Angio-guided PCI|
- Major Adverse Cardiac Events [ Time Frame: 1 year ]All cause death, Documented myocardial infarction, Repeat revascularization (PCI and/or CABG) as adjudicated by the Clinical Event Committee
- Cost Effectiveness Measured as Index Procedural and Hospitalization Costs [ Time Frame: 1 year ]Costs for each strategy included the initial procedural costs and costs during the 1-year follow-up. The costs of the index procedures were calculated from the actual resource consumption by determining the amount of guiding catheters, regular wires, pressure wires, balloon dilatation catheters, stents, antiplatelet therapy, adenosine, contrast media, and hospital days used for each patient's index procedure. These were multiplied by the cost of each resource in US dollars. All costs were converted to 2008 US dollars using the consumer price index (www.bls.gov).
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00267774
|United States, California|
|Stanford University School of Medicine|
|Stanford, California, United States, 94305|
|Principal Investigator:||Nico H Pijls||Catharina Ziekenhuis Eindhoven|
|Principal Investigator:||William F Fearon||Stanford University|